Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort

Area of Science:

• Hematology
• Transplant Immunology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplant (HCT) is a complex procedure with evolving indications.
• Accurate risk stratification is crucial for patient selection, especially in higher-risk populations.
• Existing risk assessment tools require continuous validation and updates.

Purpose of the Study:

• To evaluate the performance of the new comorbidity index (HCT-CI/Age) in predicting outcomes after allogeneic HCT.
• To compare the predictive accuracy of HCT-CI/Age against the pre-transplant assessment of mortality (PAM) score.
• To determine the utility of HCT-CI/Age in identifying patients who may benefit from alternative treatment strategies.

Main Methods:

• Retrospective analysis of 114 adult patients undergoing allogeneic HCT.
• Utilized Kaplan-Meier curves, log-rank tests, Cox models, and Pearson correlation for analysis.
• Compared the predictive capabilities of HCT-CI/Age and PAM scores for overall survival and non-relapse mortality.

Main Results:

• HCT-CI/Age scores were positively correlated with mortality risk (correlation coefficient 0.43, p < 0.001).
• HCT-CI/Age accurately predicted 2-year overall survival and non-relapse mortality in distinct risk groups (p=0.004, p=0.003).
• PAM score did not significantly differentiate outcomes between low and high-risk groups (p=0.19).

Conclusions:

• The HCT-CI/Age index demonstrates superior discriminative ability compared to PAM for predicting outcomes in allogeneic HCT recipients.
• This enhanced risk stratification can guide clinical decisions, potentially identifying patients for intensified management or alternative therapies.
• Further validation in larger cohorts is warranted, but HCT-CI/Age shows promise for optimizing HCT candidate selection.